Systemic sclerosis & Raynaud's
Evaluation of Patient and Physician Assessments of Gastrointestinal Disease Activity in Systemic Sclerosis
Authors' conclusion
In the absence of objective measures of GIT disease activity in SSc, patient-reported symptoms of GIT disease could be used to indicate disease activity
Study context
- Population
- Participants from the Australian Scleroderma Cohort Study with systemic sclerosis (SSc)
- Participants
- 143 participants
- Outcome
- Association of patient-reported and physician-assessed GIT disease activity with GIT disease severity (GIT 2.0 score), symptoms and SF-36
Methodological detailslogistic regression
- Logistic regression
Main finding
As reported in the abstract
Association with GIT disease severity
Patient-reported worsening of gastrointestinal tract (GIT) symptoms in preceding month vs more severe GIT disease, OR (P < 0.01)
6.14
Patient-reported worsening of GIT symptoms vs progressive worsening GIT 2.0 severity, OR (P < 0.01)
45.98
Observational data: associations, not effects.
Further findings
New onset of reflux (only specific symptom associated with patient-reported GIT disease activity)
- OR (P = 0.04)
- 2.98
SF-36 scores
- Patient-reported and physician-assessed GIT activity not associated with SF-36 scores
Original publication
Evaluation of Patient and Physician Assessments of Gastrointestinal Disease Activity in Systemic Sclerosis. J Rheumatol. Published 15 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →